Tumor, Normal Tissue, and Plasma Pharmacokinetic Studies of Fluorouracil Biomodulation With N-Phosphonacetyl-l-aspartate, Folinic Acid, and Interferon Alfa
- 1 May 1999
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (5), 1580
- https://doi.org/10.1200/jco.1999.17.5.1580
Abstract
PURPOSE: To evaluate the effect of N-phosphonacetyl-l-aspartate (PALA), folinic acid (FA), and interferon alfa (IFN-α) biomodulation on plasma fluorouracil (5FU) pharmacokinetics and tumor and liver radioactivity uptake and retention after [18F]-fluorouracil (5-[18F]-FU) administration. PATIENTS AND METHODS: Twenty-one paired pharmacokinetic studies were completed on patients with colorectal, gastric, and hepatocellular cancer, utilizing positron emission tomography (PET), which allowed the acquisition of tumor, normal tissue, and plasma pharmacokinetic data and tumor blood flow (TBF) measurements. The first PET study was completed when the patient was biomodulator-naive and was repeated on day 8 after the patient had been treated with either PALA, FA, or IFN-α in recognized schedules. RESULTS: TBF was an important determinant of tumor radioactivity uptake (r = .90; P < .001) and retention (r = .96; P < .001), for which radioactivity represents a composite signal of 5-[18F]-FU and [18F]-labeled metabolites and catabolites. After treatment with PALA, TBF decreased (four of four patients; P = .043), as did tumor radioactivity exposure (five of five patients; P = .0437), with no change in plasma 5FU clearance. With FA treatment, there were no differences observed in whole-body metabolism, plasma 5FU clearance, or tumor and liver pharmacokinetics. IFN-α had measurable effects on TBF and 5-[18F]-FU metabolism but had no apparent affect on liver blood flow. CONCLUSION: The administration of PALA and IFN-α produced measurable changes in plasma, tumor, and liver pharmacokinetics after 5-[18F]-FU administration. No changes were observed after FA administration. In vivo effects may negate the anticipated therapeutic advantage of 5FU biomodulation with some agents.Keywords
This publication has 18 references indexed in Scilit:
- Effect of interferon on 5-fluorouracil-induced perturbations in pools of deoxynucleotide triphosphates and DNA strand breaksCancer Chemotherapy and Pharmacology, 1996
- 5-Fluorouracil versus 5-fluorouracil plus α-interferon as treatment of metastatic colorectal carcinoma. A randomized studyAnnals of Oncology, 1996
- Reappraisal of Hepatic Arterial Infusion in the Treatment of Nonresectable Liver Metastases From Colorectal CancerJNCI Journal of the National Cancer Institute, 1996
- Association of intratumoral pharmacokinetics of fluorouracil with clinical responseThe Lancet, 1994
- Chemotherapy for Colorectal CancerNew England Journal of Medicine, 1994
- Preclinical and clinical aspects of biomodulation of 5-fluorouracilCancer Treatment Reviews, 1994
- Decreased Catabolism of Fluorouracil in Peripheral Blood Mononuclear Cells During Combination Therapy With Fluorouracil, Leucovorin, and Interferon -2aJNCI Journal of the National Cancer Institute, 1992
- Rapid Automated Algorithm for Aligning and Reslicing PET ImagesJournal of Computer Assisted Tomography, 1992
- Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase.Proceedings of the National Academy of Sciences of the United States of America, 1991
- Nonlinear pharmacokinetic models for 5-fluorouracil in man: Intravenous and intraperitoneal routesCancer Cell, 1980